Steven L. Cook, who serves as the Chief Financial Officer for Omada Health, Inc. (NASDAQ:OMDA), has finalized the disposition of company equity. According to an amended Form 4 filing lodged with the Securities and Exchange Commission, Cook sold a total of 2,900 shares of common stock on June 24 and June 25, 2026. The aggregate value of these transactions amounted to $55,145.
The sales were executed under the parameters of a pre-arranged 10b5-1 trading plan. This specific plan was adopted by Cook on March 14, 2026. On June 24, the initial tranche consisted of 2,600 shares sold at a weighted average price of $19.0173 per share. Individual trades within this block ranged from $19.00 to $19.04. The subsequent day, June 25, Cook sold an additional 300 shares. These were sold at a weighted average price of $19.0033 per share, with execution prices falling between $19.00 and $19.01.
These shares were not held as open market purchases but were acquired through the exercise of stock options. On June 24, Cook exercised options to acquire 2,600 shares at an exercise price of $8.01 per share. The following day, June 25, he exercised options for an additional 300 shares, also at $8.01 per share. The total value of these acquired shares stood at $23,229. The options in question vest over time, with 1/48th of the shares vesting monthly beginning on February 1, 2024.
The amended Form 4/A filing, submitted on July 8, 2026, serves to restate an original filing dated June 26, 2026. The amendment was necessary to include the exercise transactions that were inadvertently omitted from the initial report. While the original filing had timely reported the corresponding sales, the correction adjusted the amount of securities beneficially owned following the sales.
Following these transactions, Steven L. Cook directly owns 187,209 shares of Omada Health common stock. The broader context of the company's financial performance shows revenue of $283 million over the last twelve months, accompanied by 49% revenue growth. The company carries a market capitalization of $1.37 billion. The stock has demonstrated significant momentum, climbing to $22.98. This represents a strong return over the last three months, with shares up approximately 49% over the past six months.
Recent corporate developments include the reporting of financial results for the first quarter of 2026. Omada Health surpassed expectations, posting an earnings per share (EPS) of -$0.05, compared to the anticipated -$0.08. The company’s revenue reached $78 million, representing a 42% increase from the previous year. In conjunction with the earnings announcement, Citizens raised its price target for Omada Health to $21, up from $18, while maintaining a Market Outperform rating. Analyst Constantine Davides from Citizens highlighted that Omada Health has been trading at an average of 3.3 times forward revenue since its IPO in June 2025.
Corporate governance updates also surfaced from Omada Health’s 2026 Annual Meeting of Stockholders. The meeting resulted in the election of Sean Duffy and Trevor Fetter as Class I Directors. Both directors will serve until the 2029 annual meeting, according to the SEC filing. These developments reflect significant activity and interest in Omada Health’s financial and corporate governance landscape.
Valuation assessments present a contrasting view to the recent price appreciation. According to InvestingPro analysis, OMDA appears overvalued at current levels based on its Fair Value assessment, placing it among stocks on the Most Overvalued list. InvestingPro offers 12 additional exclusive tips for OMDA, including insights on analyst earnings revisions and profitability expectations. Investors seeking deeper analysis can access the comprehensive Pro Research Report, available for OMDA and 1,400+ other US equities.